Panel Discussion: Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients

Authors

  • Ronan Foley, MD, FRCPC
  • Carolyn Owen, MD, FRCPC
  • Samer Tabchi, MD
  • Ghazaleh Shoja E. Razavi, MD, PhD

DOI:

https://doi.org/10.58931/cht.2022.1S1029

Abstract

Approximately 40% of Diffuse large B cell lymphoma (DLBCL) patients relapse or do not respond to first line therapy. Deciding whether to pursue intensive therapies in these patients is complex, given the limited therapeutic access landscape for R/R DLCBL patients, as well as the risk of serious adverse events. Emerging therapies open up new possibilities.

Author Biographies

Ronan Foley, MD, FRCPC

Dr. Ronan Foley is a clinical hematologist with an active practice in malignant hematology at the Juravinski Cancer Centre and Director of the Hamilton Health Sciences Clinical Stem Cell Laboratory. Dr. Foley is a Professor of Pathology and Molecular Medicine at McMaster University, Past President of CBMTG, a Director of the Clinical Trials Network, and a member of the NIH Consensus Panel for the Diagnosis and Classification of Chronic Graft vs. Host Disease, along with several other affiliations. His other activities include board membership on OCREB and panel chair for the CIHR CBT panel. Dr. Foley’s current research focus is the development of therapeutic cell-based autologous vaccines. He has held grants with CANVAC, OICR, CIHR, OCRN, and CBCRA.

Carolyn Owen, MD, FRCPC

Dr. Carolyn Owen is an Associate Professor in the Division of Hematology & Hematological Malignancies at the University of Calgary. She completed internal medicine training in Ottawa and Hematology training in Vancouver followed by a research fellowship in molecular genetics at Barts and the London School of Medicine in London, UK. Her prior research is focused on familial myelodysplasia and acute myeloid leukemia. Her current clinical interests are low grade lymphoma and chronic lymphocytic leukemia and she is the local principal investigator at the Tom Baker Cancer Centre for several clinical trials in these areas.

Samer Tabchi, MD

Dr. Samer Tabchi is a hematologist/oncologist currently practicing in Rouyn-Noranda, covering the Abitbi-Temiscaming region of Quebec. He completed his initial medical training in hematology/oncology at Hotel-Dieu de France Hospital in Beirut, Lebanon. He did a Fellowship in thoracic oncology at the Centre Hospitalier de l’Université de Montréal (CHUM) in Quebec, and a second fellowship in lymphoma and myeloma at MD Anderson Cancer Center, Texas. He has also completed an additional Masters in advanced oncology from Ulm University in Germany.

Ghazaleh Shoja E. Razavi, MD, PhD

Dr. Ghazaleh Razavi graduated from medical school in 1997 and gained her board certification in general internal medicine in 2002. She achieved further board certification in hematology and medical oncology in 2006. Dr. Razavi conducted Immuno-oncology research at Georgia Cancer, University of Augusta in 2016 and completed her clinical fellowship in malignant hematology and stem cell transplantation with the Saskatoon Cancer Agency in 2017. She is a practicing hematologist and clinical assistant professor at the University of Calgary since 2019.

Downloads

Published

2022-10-30

How to Cite

1.
Foley R, Owen C, Tabchi S, Razavi G. Panel Discussion: Treatment options for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) patients. Can Hematol Today [Internet]. 2022 Oct. 30 [cited 2024 Dec. 21];1(S10). Available from: https://canadianhematologytoday.com/article/view/29

Issue

Special Supplement, October 2022

Section

Articles

License

Copyright (c) 2022 Canadian Hematology Today

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.